Enlivex Therapeutics
Quarterly Financials
| Values in thousands | 2025-12-31 | 2025-09-30 |
|---|---|---|
Revenue | $0 | $0 |
Gross Profit | -76 | -81 |
EBITDA | -5,785 | -2,124 |
EBIT | -5,861 | -2,205 |
Net Income | 1,243,053 | -2,205 |
Net Change In Cash | 0 | 0 |
Free Cash Flow | -2,911 | -2,319 |
Cash | 2,007 | 4,196 |
Basic Shares | 3,213 | 1,603 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -332 | -545 | -835 | -777 |
EBITDA | -14,668 | -14,469 | -28,219 | -25,020 |
EBIT | -15,000 | -15,014 | -29,054 | -25,797 |
Net Income | 1,235,528 | -15,014 | -29,068 | -31,060 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -10,484 | -13,111 | -23,759 | -32,075 |
Cash | 2,007 | 3,301 | 813 | 49,945 |
Basic Shares | 3,233 | 1,367 | 1,238 | 1,226 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-06-30 | -$1.20 |
2026-03-31 | -$0.15 |
2025-12-31 | -$1.41 |
2025-09-30 | -$1.35 |